OncoMatch/Clinical Trials/NCT02974647
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Is NCT02974647 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Ruxolitinib for lymphoma.
Treatment: Ruxolitinib — The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Biomarker criteria
Excluded: JAK2 fusion
T-cell Lymphoproliferative diseases with JAK2 fusion [excluded]
Disease stage
Required: Stage IB OR GREATER (FOR CTCL) (Lugano Classification (systemic lymphoma); mSWAT (CTCL))
For CTCL, patients with stage IB disease or greater are eligible. Measurable disease defined by: Lugano Classification for systemic lymphoma or Atypical and or malignant lymphocytes quantifiable by flow cytometry or morphology in blood or bone marrow or mSWAT > 0 or Sezary count ≥ 1000 cells/μL for CTCL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic anti-cancer therapy
Relapse or refractory disease after at least 1 systemic therapy except for T-PLL, LGL, or T-cell Lymphoproliferative diseases with JAK2 fusion
Cannot have received: JAK inhibitor (ruxolitinib)
Prior therapy with ruxolitinib
Lab requirements
Blood counts
ANC ≥ 1.0/mm^3 or ≥ 0.5/mm^3 if baseline neutropenia due to lymphoma; platelets ≥ 100 x 10^9/L or ≥ 50 x 10^9/L if related to lymphoma; Hgb ≥ 8g/dL; LGL or T-PLL not required to meet minimum ANC or hemoglobin
Kidney function
Creatinine clearance ≥ 30 mL/min; creatinine clearance of 15-29 mL/min allowed if baseline platelets ≥ 150 x 10^9/L
Liver function
Total bilirubin ≤ 1.5 x ULN or ≤ 3 x ULN if documented hepatic involvement with lymphoma, or ≤ 5 x ULN if history of Gilbert's; AST and ALT ≤ 3 x ULN; ≤ 5 x ULN if due to lymphoma involvement
Patients must meet the following lab criteria: ANC ≥ 1.0/mm^3 or ≥ 0.5/mm^3 (if patient has baseline neutropenia due to lymphoma), platelets ≥ 100 x 10^9/L or ≥ 50 x 10^9/L (if related to lymphoma), Hgb ≥ 8g/dL; LGL or T-PLL not required to meet a minimum ANC or hemoglobin value for eligibility; Total bilirubin ≤ 1.5 x ULN or ≤ 3 x ULN if documented hepatic involvement with lymphoma, or ≤ 5 x ULN if history of Gilbert's; AST and ALT ≤ 3 x ULN; ≤ 5 x ULN if due to lymphoma involvement; Creatinine clearance ≥ 30 mL/min; creatinine clearance of 15-29 mL/min will be allowed as long as baseline platelets are ≥ 150 x 10^9/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
- Northwestern Medicine (Data collection and specimen analysis) · Chicago, Illinois
- Dana Farber Cancer Institute · Boston, Massachusetts
- Memorial Sloan Kettering Basking Ridge · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02974647 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior JAK inhibitor disqualifies patients from enrollment.
Are patients with JAK2 alterations eligible?
No. JAK2 fusion is an exclusion criterion.
What disease stage is eligible?
Stage IB OR GREATER (FOR CTCL) is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages